Exelixis Inc

+0.24 (+1.12%)
Products, Regulatory

Exelixis Inc Says Co Has Now Assumed Responsibility For Future Clinical Development, Commercialization And Global Manufacturing Of Xl114

Published: 10/14/2021 12:13 GMT
Exelixis Inc (EXEL) - Exelixis In-licenses Second Anti-cancer Compound From Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-hodgkin’s Lymphoma.
Exelixis Inc - Co Has Now Assumed Responsibility for Future Clinical Development, Commercialization and Global Manufacturing of Xl114.
Exelixis Inc - Will Soon Initiate a Phase 1 Clinical Trial Evaluating Xl114 Monotherapy in Patients With Non-hodgkin's Lymphoma.
Exelixis Inc - Will Make an Option Exercise Payment of $10 Million to Aurigene.